Skip to content

The Effects of a Ficus Carica in Subjects With Functional Constipation

Randomized, Double-Blind, Placebo-Controlled, Parallel Trial in Subjects With Functional Constipation, to Evaluate the Improvement in Constipation of Ficus Carica

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02138851
Enrollment
80
Registered
2014-05-15
Start date
2013-06-30
Completion date
2013-12-31
Last updated
2016-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Constipation

Brief summary

The investigators performed a 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Fig paste on functional constipation. The investigators measured colon transit time, frequency of defecation, defecation time, stool type, and abdominal discomfort.

Interventions

DIETARY_SUPPLEMENTFicus Carica (300g/day)

Ficus Carica (300g/day), parallel design

DIETARY_SUPPLEMENTPlacebo (300g/day)

Placebo (300g/day), parallel design

Sponsors

Chonbuk National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* age between 19 and 39 years, * diagnosis of functional constipation by ROME III criteria, * Colon transit time (CTT) ≥ 36 h, * subjects giving written informed consent

Exclusion criteria

* allergic or hypersensitive response to any of the ingredients in the test products, * having previous history or current disease of digestive system, cardiovascular system, endocrine system and neurological disorder, * diagnosis of irritable bowel syndrome by ROME III criteria, etc,.

Design outcomes

Primary

MeasureTime frameDescription
Changes in colon transit time8 weeksColon transit time was measured in study baseline and visit 3(8 week). Colonic transit time was measured by the method of Metcalf et al,. Subjects ingested a once-daily series of three distinctive ColomarkTM capsules at the same time each day for three consecutive days. Each capsule contained twenty radioopaque makers of a ring shape. Subjects then received abdominal X-rays 24 after the ingestion of the final capsule. Abdominal X-rays through a Number of markers present was confirmed. The CTT was calculated as the sum of the markers detected on X-ray.

Secondary

MeasureTime frameDescription
Changes in frequency of defecation8 weekFrequency of defecationI was measured in study baseline and visit 3(8 week).
Changes in defecation time8 weekDefecation time was measured in study baseline and visit 3(8 week).
Changes in stool type8 weekStool type was measured in study baseline and visit 3(8 week). Stool type is composed as follows: Separate hard lumps, like nuts. (score 1); Sausage-shaped but lumpy (score 2); Like a sausage or snake but with cracks on its surface (score 3); Like a sausage or snake, smooth and soft. (score 4); Soft blobs with clear-cut edges (score 5); Fluffy pieces with ragged edges, a mushy stool (score 6); Watery, no solid pieces (score 7). The average score is closer to the three-point mode means a normal stool.
Changes in abdominal discomfort8 weekAbdominal discomfort was measured in study baseline and visit 3(8 week). Abdominal discomfort each question is composed as follows: Very poor (score 1); Poor (score 2); Average (score 3); Good (score 4); Very good (score 5). A higher score means severe abdominal pain.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026